Based on the Evelo Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Evelo Biosciences Inc is not available over the next 12 months. Evelo Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Evelo Biosciences Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Evelo Biosciences Inc’s stock price was USD 0.00. Evelo Biosciences Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -99.02% over the last year.
No recent analyst target price found for Evelo Biosciences Inc
No recent average analyst rating found for Evelo Biosciences Inc
Company Overview Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read Less
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 ...Read More
Frequently Asked Questions About Evelo Biosciences Inc (EVLO) Stock
Stock Target Advisor's fundamental analysis for Evelo Biosciences Inc's stock is Very Bearish.
Unfortunately we do not have enough data on EVLO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EVLO's stock to indicate what its average analyst target is.
EVLO stock's Price/Earning ratio is 2.40.
Our analysis grades EVLO stock's Price / Earning ratio at D+. This means that EVLO stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this EVLO may be fairly valued for its sector
The last closing price of EVLO's stock was USD 0.00.
The most recent market capitalization for EVLO is USD 0.03M.
Unfortunately we do not have enough analyst data on EVLO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Evelo Biosciences Inc's stock.
As per our most recent records Evelo Biosciences Inc has 66 Employees.
Evelo Biosciences Inc's registered address is 620 Memorial Drive, Cambridge, MA, United States, 02139.
You can get more information about it from Evelo Biosciences Inc's website at https://www.evelobio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Evelo Biosciences Inc (EVLO) Stock
Stock Target Advisor's fundamental analysis for Evelo Biosciences Inc's stock is Very Bearish.
Unfortunately we do not have enough data on EVLO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EVLO's stock to indicate what its average analyst target is.
EVLO stock's Price/Earning ratio is 2.40.
Our analysis grades EVLO stock's Price / Earning ratio at D+. This means that EVLO stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this EVLO may be fairly valued for its sector
The last closing price of EVLO's stock was USD 0.00.
The most recent market capitalization for EVLO is USD 0.03M.
Unfortunately we do not have enough analyst data on EVLO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Evelo Biosciences Inc's stock.
As per our most recent records Evelo Biosciences Inc has 66 Employees.
Evelo Biosciences Inc's registered address is 620 Memorial Drive, Cambridge, MA, United States, 02139.
You can get more information about it from Evelo Biosciences Inc's website at https://www.evelobio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EVLO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
